Hamburg To Advise Institute of Medicine On International Issues
This article was originally published in The Gray Sheet
Having shepherded FDA through hurdles resulting from globalization, the now-former FDA Commissioner Hamburg will advise IOM on international issues that affect the U.S. healthcare system as IOM's newly appointed foreign secretary.
You may also be interested in...
Acting FDA Commissioner says he can’t envision any new major priorities that would emerge in the short-term.
During her final public appearance at the National Press Club, outgoing FDA Commissioner Margaret Hamburg defended her tenure and said she was leaving a stronger FDA than the one she inherited. Asked about the agency's device regulatory process, she said she didn't know if FDA or Europe had struck the right balance but said more work needs to be done.
China's Hybio, Youcare and Shanxi Jinbo appear to be the only three companies in the world trying to develop a fusion inhibitor for COVID-19, the most advanced of which has now moved into a domestic Phase II trial.